CTLA4-Ig

Sarah E. Yost, Bruce Kaplan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Modern-day immunosuppression relies heavily on calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus. While dramatically reducing the rates of acute cellular rejection over the last couple of decades, these agents have numerous undesirable metabolic and cosmetic side effects. In the past, immunosuppression was based on small molecular therapy, including CNIs, prodrugs of mycophenolate mofetil, and these drugs had many undesirable side effects. Biological agents are now more frequently tested for immunosuppression, including monoclonal antibodies, agents that block stimulatory pathways, and specific receptors. Recent studies with the agent belatacept have shown promise in terms of eliminating CNIs and also eliminating the burden of toxicities that accompany their use.

Original languageEnglish (US)
Title of host publicationImmunotherapy in Transplantation
Subtitle of host publicationPrinciples and Practice
PublisherWiley-Blackwell
Pages399-406
Number of pages8
ISBN (Print)9781405182713
DOIs
StatePublished - Apr 19 2012

    Fingerprint

Keywords

  • Abatacept
  • Belatacept
  • ITLA4-Ig
  • Immunosuppression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yost, S. E., & Kaplan, B. (2012). CTLA4-Ig. In Immunotherapy in Transplantation: Principles and Practice (pp. 399-406). Wiley-Blackwell. https://doi.org/10.1002/9781444355628.ch27